Abstract
Introduction: The essential feature of borderline personality disorder (BPD) is a pervasive pattern of instability of interpersonal relationships, self-image, and affects, and marked impulsivity. While according to some studies olanzapine and aripiprazole are effective agents in BPD, there are other studies that deny such an effect. So, with respect to these controversies, an assessment was performed to compare the efficacy and safety of olanzapine vs aripiprazole in this group of patients.
Method: Twenty four patients, were entered into one of the two groups (n=12 in each group) for participating in an 8- week, open-label study for random assignment to olanzapine or aripiprazole in a 1:1 ratio. Primary outcome measure included Brief Psychiatric Rating Scale (BPRS) for estimation of baseline psychopathology, clinical outcome and treatment response. In addition, Buss-Durkee Hostility Inventory (BDHI) for the assessment of anger& hostility, and Clinical Global Impressions-Severity Scale (CGI-S), for assessment of overall illness severity were used as secondary scales. The patients were assessed by means of BPRS at baseline (week 0), and weeks 2, 4 and 8. The other scales were scored at baseline and at the end of the assessment.
Results: According to the findings both olanzapine and aripiprazole showed a significant improvement in BPRS at the end of the trial (p=0.01 and p=0.04, respectively). BDHI and CGI-S as well improved significantly by olanzapine (p=0.04 and p=0.03, respectively), while it was not so regarding aripiprazole (p=0.06 and p=0.07, respectively). Effect size (ES) analysis for changes in BPRS, indicated a large improvement with both of olanzapine and aripiprazole.
Conclusion: Both olanzapine and aripiprazole had relatively comparable effect on general symptoms of BPD, in spite of a bit greater influence of olanzapine on some of the secondary outcome measures.
Keywords: Aripiprazole, borderline personality disorder, olanzapine.
Current Psychopharmacology
Title:Olanzapine vs Aripiprazole in the Management of Borderline Personality Disorder
Volume: 3
Author(s): Saeed S. Shafti and Hamid Kaviani
Affiliation:
Keywords: Aripiprazole, borderline personality disorder, olanzapine.
Abstract: Introduction: The essential feature of borderline personality disorder (BPD) is a pervasive pattern of instability of interpersonal relationships, self-image, and affects, and marked impulsivity. While according to some studies olanzapine and aripiprazole are effective agents in BPD, there are other studies that deny such an effect. So, with respect to these controversies, an assessment was performed to compare the efficacy and safety of olanzapine vs aripiprazole in this group of patients.
Method: Twenty four patients, were entered into one of the two groups (n=12 in each group) for participating in an 8- week, open-label study for random assignment to olanzapine or aripiprazole in a 1:1 ratio. Primary outcome measure included Brief Psychiatric Rating Scale (BPRS) for estimation of baseline psychopathology, clinical outcome and treatment response. In addition, Buss-Durkee Hostility Inventory (BDHI) for the assessment of anger& hostility, and Clinical Global Impressions-Severity Scale (CGI-S), for assessment of overall illness severity were used as secondary scales. The patients were assessed by means of BPRS at baseline (week 0), and weeks 2, 4 and 8. The other scales were scored at baseline and at the end of the assessment.
Results: According to the findings both olanzapine and aripiprazole showed a significant improvement in BPRS at the end of the trial (p=0.01 and p=0.04, respectively). BDHI and CGI-S as well improved significantly by olanzapine (p=0.04 and p=0.03, respectively), while it was not so regarding aripiprazole (p=0.06 and p=0.07, respectively). Effect size (ES) analysis for changes in BPRS, indicated a large improvement with both of olanzapine and aripiprazole.
Conclusion: Both olanzapine and aripiprazole had relatively comparable effect on general symptoms of BPD, in spite of a bit greater influence of olanzapine on some of the secondary outcome measures.
Export Options
About this article
Cite this article as:
S. Shafti Saeed and Kaviani Hamid, Olanzapine vs Aripiprazole in the Management of Borderline Personality Disorder, Current Psychopharmacology 2014; 3 (2) . https://dx.doi.org/10.2174/2211556003666140912223626
DOI https://dx.doi.org/10.2174/2211556003666140912223626 |
Print ISSN 2211-5560 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5579 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
An Insight into Patents of Fluoroquinolone Derivatives
Letters in Drug Design & Discovery Fast Disintegrating Film Approach for the Oral Delivery of Zolmitriptan: Formulation, <i>In Vitro</i> and <i>In Vivo</i> Evaluation
Drug Delivery Letters <i>Dichrostachys cinerea</i>: Ethnomedicinal Uses, Phytochemistry and Pharmacological Activities - A Review
The Natural Products Journal Does Non-Invasive Brain Stimulation Improve Cognition in Major Depressive Disorder? A Systematic Review
CNS & Neurological Disorders - Drug Targets The Synthetic Cannabinoids Phenomenon
Current Pharmaceutical Design Emerging Roles of P2X Receptors in Cancer
Current Medicinal Chemistry Managing Erectile Dysfunction in Heart Failure
Endocrine, Metabolic & Immune Disorders - Drug Targets Targeting JAK/STAT Signaling Pathway in Inflammatory Diseases
Current Signal Transduction Therapy Recent Advances on the Roles of NO in Cancer and Chronic Inflammatory Disorders
Current Medicinal Chemistry Aspirin: from a Historical Perspective
Recent Patents on Cardiovascular Drug Discovery Mucopolysaccharidosis Type II (Hunter Syndrome): Clinical Picture and Treatment
Current Pharmaceutical Biotechnology Retrospective Results on the Treatment of Chronic Hepatitis C with Different Interferon Regimes in a General Hospital
Current Drug Therapy Hutchinson-Gilford Progeria Syndrome (Hgps) and Application of Gene Therapy Based Crispr/Cas Technology as A Promising Innovative Treatment Approach
Recent Patents on Biotechnology Neuroprotection by NMDA Receptor Antagonists in a Variety of Neuropathologies
Current Drug Targets The Role of Antihistamine Drugs in Allergic Disorders
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Central Nervous System Disorders Associated to Immune Checkpoint Inhibitors
Current Cancer Therapy Reviews Myelin Sheaths and Autoimmune Response Induced by Myelin Proteins and Alphaviruses. I. Physicochemical Background
Current Medicinal Chemistry Neuro-psychopharmacogenetics and Neurological Antecedents of Posttraumatic Stress Disorder: Unlocking the Mysteries of Resilience and Vulnerability
Current Neuropharmacology Blood Platelet Reactivity and its Pharmacological Modulation in (People with) Diabetes Mellitus
Current Pharmaceutical Design Drug-Induced Aseptic Meningitis
Current Drug Targets - Immune, Endocrine & Metabolic Disorders